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Abstract
Background—To evaluate the safety and clinical feasibility of focal Irreversible Electroporation 
(IRE) of the prostate.
Methods—We assessed the toxicity profile and functional outcomes of consecutive patients 
undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by 
multi-parametric MRI (mpMRI) and targeted and/or template biopsy. IRE was delivered under 
transrectal ultrasound guidance with two to six electrodes positioned transperineally within the 
cancer lesion. Complications were recorded and scored accordingly to the NCI Common 
Terminology Criteria for Adverse Events; the functional outcome was physician reported in all 
patients with at least 6 months follow-up. A contrast-enhanced MRI one week after the procedure 
was carried out to assess treatment effect with a further mpMRI at 6 months to rule out evidence 
of residual visible cancer.
Results—Overall, 34 patients with a mean age of 65 years (SD= ±6) and a median PSA of 6.1 
ng/ml (IQR= 4.3 - 7.7) were included. Nine (26%), 24 (71%) and one (3%) men had low, 
intermediate and high risk disease, respectively (D’Amico criteria). After a median follow-up of 6 
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months (range 1-24), 12 grade 1 and 10 grade 2 complications occurred. No patient had grade >/= 
3 complication. From a functional point of view, 100% (24/24) patients were continent and 
potency was preserved in 95% (19/20) men potent before treatment. The volume of ablation was a 
median 12ml (IQR= 5.6 - 14.5ml) with the median PSA after 6 months of 3.4ng/ml (IQR= 1.9 - 
4.8ng/ml). MpMRI showed suspicious residual disease in six patients, of whom four (17%) 
underwent another form of local treatment.
Conclusions—Focal Irreversible Electroporation has a low toxicity profile with encouraging 
genito-urinary functional outcomes. Further prospective development studies are needed to 
confirm the functional outcomes and to explore the oncological potential.
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focal therapy; irreversible electroporation; prostate cancer; toxicity
Introduction
The therapeutic ratio – benefit to harms - of standard therapies used in the treatment of 
localised prostate cancer is low 1. As a result, much clinical and research effort has centred 
on reducing the side-effects of current radical therapies. Focal therapy has emerged as one 
such strategy that might reduce harms whilst retaining benefit of cancer control.
Focal therapy, in its various forms, has been evaluated in early prospective proof of concept 
studies and is currently fully recruited to a randomised controlled trial in Europe 2-4. Whilst 
these studies used High Intensity Focused Ultrasound (HIFU) and Vascular Targeted 
Therapy, respectively, other studies/case series have evaluated cryotherapy and thermal 
laser 5-8. The results of all these reports have been summarised in a recent systematic 
review 9 showing that incontinence is 0-5%, impotence is 0-46% and disease control using 
biopsies is 77-96.3%. Early toxicity from these various ablative modalities can be high with 
recto-urethral fistula reported in up to 2.4% patients.
Irreversible Electroporation (IRE) is a non-thermal energy source that is being used in the 
USA and in Europe by interventional radiologists in liver, kidney and pancreas in a primary, 
salvage and palliative role 10-13. Although it is approved and being used in both jurisdictions 
in the treatment of prostate cancer, only few case reports of its use in this role exist in the 
urological literature 14,15.
This report combines the work of two groups working independently who adopted the IRE 
technology early and applied it very selectively in a real practice clinical setting with careful 
institutional audit of results.
Materials and Methods
Design/Population
This is a two-centre (Princess Grace Hospital in London/UK, and St.Vincent’s Prostate 
Cancer Centre, Sydney/Australia) retrospective analysis of men with localised prostate 
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cancer treated with IRE. It represents the two learning curves within these two institutions 
(August 2011 to August 2013). Internal Review Board exemption was granted.
As part of the local approach for accurately characterising treatment-naïve patients 
interested in tissue-preserving approaches, all men underwent multi-parametric MRI (1.5 or 
3T mpMRI with a pelvic coil; T2-weighted/dynamic-contrast enhanced/diffusion-weighted 
sequences; the OsiriX® Imaging Software was used for post-acquisition processing and 
reporting) and histological verification of suspicious areas by targeted and/or transperineal 
template mapping biopsy. All patients in this cohort had one MRI visible lesion concordant 
with histological findings showing clinically significant prostate cancer in this area. Any 
Gleason pattern >/=4 and/or cancer core length >/=4mm was considered clinically 
significant cancer. Informed consent was obtained from all patients after thoroughly 
discussing the potential risks along with the possible advantages of this new technology.
Procedure
IRE was delivered using the Nanoknife™ System (AngioDynamics®, Queensbury, NY, 
USA). The Nanoknife System is composed of a generator, which deploys low-energy direct 
current (LEDC) that leads to cell death by the formation of nanopores within the cell 
membrane rather than heating effect 16,17. According to the treatment strategy and to the 
characteristics of the area to target, a certain number of needles are positioned to delineate 
the treatment area. Maximum electrode exposure length per needle is 2cm, and the distance 
between two needles should not exceed 2cm again; therefore, the number of needles was 
proportional to the treatment area. Once, the electrodes have been inserted, the distances 
between each two electrodes are measured on the transrectal ultrasound axial view. The 
device was set to deliver 90 pulses with a pulse length at 70μsec. The treatment to deliver 
was then automatically calculated by the system on the basis of the number of needles 
employed, the distances between them and the active electrode length used in order to obtain 
an optimal electrical field between 20-40 Ampere, which seems to causes complete ablation 
within the target area with no thermal damage 16. Before delivering all the 90 pulses, a ‘test 
pulse’ at 10 pulses was delivered in order to verify the actual electrical field in the tissue. 
Indeed, current above the upper threshold of 40 Ampere may cause out-field treatment and 
heating damage, whereas current below the lower limit of 20 Ampere may lead to under-
treatment. Therefore, if the current was in this range, the remaining 80 pulses were 
delivered, whereas in the opposite case the treatment planning was modified. Of note, the 
system calculates the current separately between every two needles, so it is possible to 
modify selectively the treatment only in the area needed without affecting the remaining 
parameters.
Electrodes were positioned at the margin of the lesion under transrectal ultrasound guidance 
using a brachytherapy stepper and grid set up (Figure 1). As this was part of the learning 
curve of both institutions, it was not possible to standardise the intervention. Men treated in 
the early part of the experience had small volume lesions, and were treated cautiously with 2 
electrodes into the target area. As experience accumulated, in an iterative manner, targets of 
greater volume were targeted with 4-6 needles. Since the maximum electrode exposure 
length is 2cm, if a lesion was long than this in the ‘Z’ plane of the prostate, a pull-back and 
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second treatment was used. The target volume was defined by mpMRI and histopathology 
with a safety margin of 3-5 mm.
Intravenous cefuroxime and gentamicin antibiotics were administered at induction; patients 
were under general anaesthesia with deep muscle paralysis using pancuronium bromide. 
Continuous peri-operative electrocardiographic monitoring with ECG was maintained. 
Urinary catheters were managed differently in the two centres. The Princess Grace Hospital 
cohort had either a urethral or a supra-pubic catheter placed at the time of the procedure, and 
a first attempt to remove the catheter was performed between three and five days after 
treatment. At St. Vincent’s Prostate Cancer Centre, a urethral catheter was inserted for the 
procedure, and removed at the end of the procedure unless the target lesion abutted the 
urethra.
Follow-up
Early contrast-enhanced MRI was obtained after one week to evaluate local effect of the 
treatment, and to rule-out rectal damage which might indicate a recto-urethral fistula. On 
this scan, the ablation area was calculated by planimetry. Patients were then followed up by 
clinical visits with serum PSA levels every three months. Also, a late mpMRI was 
performed six months after the procedure, and then once a year. All MRIs were reported by 
one experienced radiologist per centre using the Likert scale to define the likelihood of 
residual disease (1= extremely unlikely; 2= unlikely; 3= equivocal; 4= likely; 5= extremely 
likely). Residual disease was evaluated by comparing post-IRE MR-images with pre-
operative scans in which the treated lesion was visible. Residual cancer was suspected in 
case of an early enhancing focus on dynamic contrast sequence and residual restricted 
diffusion in the treatment area. In this study, values 3 to 5 were considered suspicious for 
residual cancer. During the perioperative period and the follow-up, complications were 
reported per type, and retrospectively scored according to the NCI Common Terminology 
Criteria for Adverse Events version 4.0 (CTCAE). Genito-urinary outcome is only reported 
for patients who were potent and/or continent before treatment, and with at least six months 
follow-up. Potency and urinary continence were physician-evaluated on the basis of patient 
reported ability to have erections sufficient for penetrative sexual intercourse and no pad 
use, respectively. The use of pre-operative and post-operative PDE-5 inhibitors was not 
systematically recorded.
Statistics
Continuous variables are given using the mean ± standard deviation (SD), or using the 
median and the overall/ interquartile range (IQR) according to their distribution; categorical 
variables are given using frequencies and percentages. Each patient was censored up to the 
time of last follow-up. All analyses were performed using SPSS® version 20.0 (Armonk, 
NY: IBM corporation).
Results
Overall, 34 patients were treated using primary focal IRE across the two centres, Princess 
Grace Hospital (n=20) and St. Vincent Prostate Cancer Centre (n=14). Basic patients’ 
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characteristics and histological findings are summarized in table 1. Mean age was 65 ± 6 
years; median PSA was 6.1 ng/ml (IQR= 4.3 - 7.7). A few men (n=2; 6%) had only 
transperineal targeted biopsy, whereas the majority (n=32; 94%) had template prostate 
mapping with additional targeted biopsy, although the biopsy density was variable, as shown 
in table 1. According to the D’Amico risk stratification nine (26%), 24 (71%) and one (3%) 
patients were stratified as low, intermediate and high risk, respectively.
Table 2 summarises the perioperative outcomes. In each patient, a median of four probes 
were employed, the median operative time from insertion of needles to completion was 27 
minutes (range 11-55). Thirty-two patients (94%) were discharged the same evening of the 
day of the procedure and two stayed overnight. In nine (26%), no catheter was inserted 
during the procedure, whereas in the remaining either a supra-pubic (n= 9; 26%) or an 
urethral catheter (n= 16; 48%) was inserted. Median catheterisation length was 3 days 
(range= 0 - 9).
Toxicity
Genito-urinary toxicity is displayed in table 3; overall adverse events stratified by the NCI-
CTCAE grade are displayed in table 4. All complications were grade 1 or 2, and no severe 
adverse event occurred. No patients had a recto-urethral fistula, and none had a urethral 
stricture. Non genitourinary adverse events occurred in four men. One patient had self-
resolving per-operative tachycardia requiring 24-hour inpatient surveillance with no 
additional intervention; one patient stayed over-night for ‘social reasons’; and two patients 
needed prolonged wound dressing at the site of the suprapubic catheter following catheter 
removal.
Successful catheter withdrawal at first attempt was achieved in 32 patients (94%). Some 
patients had either dysuria (n=6; 18%), or debris and/or hematuria (n=5; 15%) at one of the 
follow-up visits. Five patients (15%) developed uncomplicated urinary tract infection that 
were all managed with oral antibiotics.
Functional Outcome
Median follow-up was six months (range= 1–24) with 24 patients (71%) having a follow-up 
of at least 6 months (table 5). Potency was preserved in 95% (19/20) potent men before 
treatment, whereas all men continent before treatment were still continent (no pad usage) 
after treatment (24/24). No rectal dysfunction was recorded; however, this was probably not 
specifically and systematically investigated at follow-up.
Early disease control
On early MRI, the ablation area was estimated to be a median of 12ml (IQR= 5.6 - 14.5ml) 
(figure 2). Median PSA at 6 months was 3.2ng/ml (IQR= 1.9 - 4.8). In the follow up period, 
mpMRI showed suspicious residual disease in six patients. Two of these patients remain on 
surveillance since the PSA dropped significantly from pre-operative values. Four patients 
(17%) underwent a secondary treatment. Three patients had a secondary focal ablation in the 
same area, one using IRE and two using HIFU. Only one patient had histological 
verification of failure with transperineal targeted biopsy detecting residual Gleason 3 + 4. 
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He chose to undergo radical prostatectomy, which showed residual disease stage T2c 
Gleason 3 + 4. Unfortunately, the procedure was performed in another institution, and no 
zonal analysis was reported; therefore, it was not possible to determine the local effect of 
IRE in the treated area. Greater follow-up is required to determine the success of this further 
therapy. No patient died, had metastasis, or switched to systemic treatment.
Discussion
This study shows that focal IRE seems to be well tolerated in a heterogeneous group of 
patients across two centres. The genito-urinary outcomes, in terms both of erectile function 
and urinary continence, appear particularly encouraging. Longer follow-up in a protocol 
driven study is needed to derive any conclusion with respect to the cancer-control outcomes.
Limitations
Before discussing our findings, it is important to acknowledge the limitations of this study. 
First, the functional outcomes are reported on the basis of physician-reported measures, so 
may be overestimated. We are currently recruiting to a prospective ethics committee 
approved registered trial in the UK with embedded patient questionnaires to overcome this 
shortcoming 18. Second, both the short follow-up and the absence of systematic histological 
verification of complete ablation in the treatment area do not allow us to draw any 
conclusion with respect to the efficacy of IRE in prostate cancer. In fact, as PSA kinetics 
alone are not specific enough to predict recurrence after focal treatment, we also used 
postoperative mpMRI to determine local failure. Although this tool seems promising in 
detecting recurrent disease after tissue-preserving treatment, it has not been validated yet in 
IRE 19-21. Third, heterogeneity clearly exists in terms of patients’ characteristics, selection 
of patients and standard operating procedures. All patients underwent mpMRI for eligibility, 
but the histological verification modality ranged from a few targeted biopsies of suspicious 
areas to full prostate mapping with additional samples derived from MRI-targets according 
to physicians’ choice and preoperative mpMRI results. While this might have hindered the 
selection of patients, in both centres the diagnostic accuracy of the mpMRI protocol has 
been previously verified and negative predictive value for ruling out significant disease was 
at 90-95% 22,23. Fourth, the retrospective nature of the study along with the small sample 
size represent additional limitations.
Clinical Implications
A recent systematic review of ablation modalities used for focal treatment of prostate cancer 
has shown that various modalities have been already used in selected patients with variable 
results 9. However, IRE might have potential advantages over these. First, the non-thermal 
nature of the tissue damage seems to lead to very tight cell-kill zones in animal experiments 
and this might have advantages in prostate cancer focal therapy by allowing greater control 
over ablation of the target area 24. Further, the local ablation should not be hindered by the 
so called ‘heat sink’ effect that can limit the efficacy of thermal ablation.
Another potential characteristic of IRE is the possibility of tissue-selectivity. Animal studies 
have shown that when an appropriate electrical field is employed, complete destruction of 
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the target area can be achieved without damaging the collagenous structures - such as 
nerves, vessels and the urethra. In randomized controlled studies in which IRE was delivered 
to 30 rat sciatic nerves, whilst there was a decrease in nerve conductivity immediately after 
the procedure, after seven weeks, electrophysiological, functional and histological findings 
showed that the nerves had fully recovered 25. Similar findings were demonstrated in focal 
IRE of canine prostates, in which the urethra and the neurovascular bundles were not 
affected histologically 24,26.
Finally, the procedure time is considerably shorter compared to other focal treatments. This 
is due to the fact that once the needles are positioned, the exposure time for a complete 
ablation is less than five minutes per lesion.
The interesting finding in this study remains the low toxicity, with no severe complication 
after treatment, and no recto-urethral fistulae. If we compare these results with the toxicity 
and the functional outcomes of current technologies used in focal therapy in prostate cancer, 
IRE is certainly encouraging 9. This low toxicity is probably related to the inner 
characteristics of the energy discussed above.
From a disease control point of view, it is difficult to draw any definitive conclusions. This 
series should be regarded as the first step in the investigation of IRE in clinical studies. 
Recently, guidelines have been issued to guide researchers on how to assess new 
technologies in surgery 27-29. This framework includes an initial phase of liberal, but safe 
clinical assessment by experts in the field 27. Experience gained through this phase has 
allowed standardisation of the technique to take place through an iterative process of 
modifications to the technique. As a result, recruitment to a prospective development study 
evaluating disease control outcomes with post-treatment biopsies as well as prospective 
patient reported outcomes on genitourinary and rectal function has just begun 18. Focal IRE 
may enhance the perioperative outcome and the functional preservation in patients 
undergoing prostate cancer focal treatment. However, rigorous prospective studies with 
systematic assessment of the functional and of the oncological outcomes are needed in order 
to move forward in the evaluation of this new technology.
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Figure 1. This figure shows a representation of the electrodes used for Irreversible 
Electroporation with the Nanoknife® system (Image Courtesy of AngioDynamics).
For each treatment, one activator probe (blue probe) is always needed and up to five 
standard probes (white probe) are employed, according to the size of the lesion. For both 
probes, a thumb slide situated at the handle of the electrode (green arrow) controls an 
adjustable insultation sheath which exposes the active length (red arrow) when retracted. In 
this representation, an active length exposure at 1.5cm is set.
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Figure 2. The left image shows a preoperative contrast-enhanced MR sequence highlighting a 
suspicious lesion in the left anterior area of the prostate. The right image shows successful 
ablation of this lesion with limited damage to surrounding structures after focal irreversible 
electroporation.
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Table 1
Clinical and histological characteristics of patients undergoing focal Irreversible 
Electroporation.
Variable Value
Age in years (mean ± SD) 65 ± 6
PSA in ng/ ml (median; IQR) 6.1; 4.3 – 7.7
Prostate Volume in ml (mean ± SD) 42.4 ± 14.6
Number of Cores Taken (median; IQR) 25; 19 – 29
Number of Positive Cores (median; IQR) 3; 2 – 5
Biopsy Density - no of cores/ prostate ml (median; IQR) 0.6 (0.43 - 0.78)
Maximum Cancer Length in mm (mean ± SD) 6 ± 3
% Maximum Cancer Length (mean ± SD) 50 ± 30%
Gleason Score
3 + 3 9 (26%)
3 + 4 19 (56%)
4 + 3 5 (15%)
4 + 4 1 (3%)
Risk Classification (D’Amico)
Low 9 (26%)
Intermediate 24 (71%)
High 1 (3%)
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Table 2
Perioperative outcome after focal Irreversible Electroporation
Variable Value
Number of probes used (overall range) 4 (2 – 6)
Procedure time in min. (overall range) 27 (11 – 55)
Catheterisation at the time of surgery
None 9 (26%)
Suprapubic 9 (26%)
Urethral 16 (48%)
Hospital Stay in days (overall range) 1 (1 – 2)
Catheterisation Time (overall range) 3 (0 – 9)
Successful voiding after first catheter withdrawal 32/ 34 (94%)
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Table 3
Genito-urinary and rectal toxicity after focal Irreversible Electroporation.
Toxicity Event Number of Patients (%)
Urethral Stricture 0
Urinary Retention 2 (6%)
Debris and/ or hematuria 6 (18%)
Dysuria 5 (15%)
Urinary tract infection 5 (15%)
Recto-Urethral Fistulae 0
Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2015 June 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Valerio et al. Page 15
Table 4
Overall toxicity classified according to the Common Terminology Criteria for Adverse 
Events v4.0 (CTCAE).
CTCAE Grade Definition Number of Patients 
(%)
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not 
indicated
12 (35%)
2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate 
instrumental activities of daily living
10 (29%)
3 Severe or medical significant, but not immediately lifethreatening; hospitalization or prolongation 
of hospitalization indicated; disabling; limiting self care activities of daily living
0
4 Life-threatening consequences; urgent intervention indicated. 0
5 Death related to Adverse Event 0
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Table 5
Functional and oncological outcomes after focal Irreversible Electroporation.
Variable Value
Follow-up in months (median; overall range) 6 ; 1 – 24
No of patients with at least 6 months follow-up 24 (71%)
Potency Preservation 19/ 20 (95%)
Continence Preservation 24/ 24 (100%)
Volume ablated on MRI in ml (median; IQR) 12; 5.6 - 14.5
PSA at 6 months (median; IQR) 3.4; 1.9 – 4.8
Secondary Treatment 4/ 24 (17%)
Metastasis or Death 0
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